Shao, 131 patient paxlovid early treatment study: 20% faster viral clearance [p=0.0006] https://c19p.org/shao
copied to clipboard
Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China
et al., medRxiv, doi:10.1101/2022.07.03.22277169 (Preprint)
Retrospective 17 paxlovid and 114 lianhuaqingwen patients in China, showing faster viral clearance with paxlovid.
|
time to viral-, 20.0% lower, relative time 0.80, p < 0.001, treatment 17, control 114.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Shao et al., 7/6/2022, retrospective, China, preprint, median age 52.0, 12 authors, study period 6 April, 2022 - 11 May, 2022, this trial compares with another treatment - results may be better when compared to placebo.
Contact:
huanggang@sumhs.edu.cn, hujianrong@jdhospital.com.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.